Lymphoplasmacytic lymphoma and Waldenström macroglobulinaemia: clinicopathological features and differential diagnosis

Wang, Wei; Lin, Pei

doi:10.1016/j.pathol.2019.09.009

Cited by 25 publications

(36 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have demonstrated the deregulation of genes associated with the Wnt pathway in B-cell disorders and MM. Indeed, the transcriptional factor LEF1 was under expressed in WM and IgM MGUS vs. CTRLs as well as vs. CLL B-cells [5,15,41,42]. Moreover, LEF1 was over expressed in immature normal B-cells compared to mature normal B-cells [42].…”

Section: Adherens Junctions and Wnt Signaling Pathwaymentioning

confidence: 99%

Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenström Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma Cells

Trojani

Camillo

Bossi

et al. 2021

Cancers

View full text Add to dashboard Cite

Waldenström Macroglobulinemia (WM) is a B-cell lymphoma characterized by the precursor condition IgM monoclonal gammopathies of undetermined significance (IgM MGUS). We performed a gene expression profiling study to compare the transcriptome signatures of bone marrow (BM) B-cells and plasma cells of 36 WM patients, 13 IgM MGUS cases, and 7 healthy subjects used as controls (CTRLs) by Affymetrix microarray. We determined 2038 differentially expressed genes (DEGs) in CD19+ cells and 29 DEGs genes in CD138+ cells, respectively. The DEGs identified in B-cells were associated with KEGG pathways, mainly involved in hematopoietic cell lineage antigens, cell adhesion/focal adhesion/transmembrane proteins, adherens junctions, Wnt-signaling pathway, BCR-signaling pathway, calcium signaling pathway, complement/coagulation cascade, platelet activation, cytokine-cytokine receptor interactions, and signaling pathways responsible for cell cycle, apoptosis, proliferation and survival. In conclusion, we showed the deregulation of groups of genes belonging to KEGG pathways in the comparison among WM vs. IgM MGUS vs. CTRLs in B-cells. Interestingly, a small set of genes in B-cells displayed a common transcriptome expression profile between WM and IgM MGUS compared to CTRLs, suggesting its possible role in the risk of transformation of IgM MGUS to WM.

show abstract

Section: Adherens Junctions and Wnt Signaling Pathwaymentioning

confidence: 99%

Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenström Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma Cells

Trojani

Camillo

Bossi

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Normally, MYD88 encodes for a protein that activates the MAPK and NF-KB pathways which subsequently cause proliferation and survival of B-cells. The L265P mutation constitutively activates the NF-KB pathway which leads to tumorogenesis [ 75 , 76 ]. Approximately 30% of LPL/WM have mutated CXCR4 [ 77 ].…”

Section: Lymphoplasmacytic Lymphomamentioning

confidence: 99%

“…CXCR4 is a chemokine receptor which when mutated, can prolong stimulation of CXCL2/SDF1, its ligand, increasing adhesion and migration into the bone marrow [ 78 , 79 ]. Cytogenetic studies show del(6q) and t(9;14)(p13;q32) in up to 50% of cases and trisomy 4 in approximately 20% [ 76 , 79 , 80 , 81 ]. Deletion of 6q may lead to the loss of two tumor suppressor genes, BLIMP1 (6q21) and TNFAIP3 (6q23).…”

Section: Lymphoplasmacytic Lymphomamentioning

confidence: 99%

CD5-Negative, CD10-Negative Low-Grade B-Cell Lymphoproliferative Disorders of the Spleen

Schmieg¹,

Muir²,

Aguilera

et al. 2021

Current Oncology

View full text Add to dashboard Cite

CD5-negative, CD10-negative low-grade B-cell lymphoproliferative disorders (CD5-CD10-LPD) of the spleen comprise a fascinating group of indolent, neoplastic, mature B-cell proliferations that are essential to accurately identify but can be difficult to diagnose. They comprise the majority of B-cell LPDs primary to the spleen, commonly presenting with splenomegaly and co-involvement of peripheral blood and bone marrow, but with little to no involvement of lymph nodes. Splenic marginal zone lymphoma is one of the prototypical, best studied, and most frequently encountered CD5-CD10-LPD of the spleen and typically involves white pulp. In contrast, hairy cell leukemia, another well-studied CD5-CD10-LPD of the spleen, involves red pulp, as do the two less common entities comprising so-called splenic B-cell lymphoma/leukemia unclassifiable: splenic diffuse red pulp small B-cell lymphoma and hairy cell leukemia variant. Although not always encountered in the spleen, lymphoplasmacytic lymphoma, a B-cell lymphoproliferative disorder consisting of a dual population of both clonal B-cells and plasma cells and the frequent presence of the MYD88 L265P mutation, is another CD5-CD10-LPD that can be seen in the spleen. Distinction of these different entities is possible through careful evaluation of morphologic, immunophenotypic, cytogenetic, and molecular features, as well as peripheral blood and bone marrow specimens. A firm understanding of this group of low-grade B-cell lymphoproliferative disorders is necessary for accurate diagnosis leading to optimal patient management.

show abstract

“…When these cells infiltrate the BM and are associated with a plasma peak of IgM (macroglobulinemia), the disease is named after Jan Waldenström . Waldenström macroglobulinemia (WM) is thus typically characterized by splenomegaly and monoclonal hypergammaglobulinemia of IgM isotype . There are no specific immunophenotypic features of this disorder.…”

Section: Cd5‐negative B‐lpdsmentioning

confidence: 99%

Flow cytometry in the diagnosis of mature B‐cell lymphoproliferative disorders

Debord

Wuillème

Eveillard

et al. 2020

Int J Lab Hematology

View full text Add to dashboard Cite

B-lineage lymphoproliferative disorders (LPD) are rather frequent diseases, associated with specific clinical or biological features but also sometimes of fortuitous discovery. Multiparameter flow cytometry plays a major role for a rapid diagnostic indication, on peripheral blood or bone marrow samples in most instances, guiding complementary analyses and allowing for the proper therapeutic management of patients. After describing the important pre-analytical precautions required for an adequate assessment, the immunophenotypic features of small-cell and large-cell lymphomas are described in this review. The ubiquitous expression of CD19 is a first mandatory gating step. A possible clonal proliferation is then suspected by the demonstration of surface immunoglobulin light chain restriction. The aberrant presence of CD5 allows to segregate chronic lymphocytic leukemia and mantle cell lymphoma in most cases. Other LPD exhibit specific immunophenotypic features. A table of useful markers and a decision tree are provided. Of note, immunophenotypic data should as much as possible be interpreted in an integrated manner, involving the patient's clinical and other biological features, and be completed by further chromosomal and/or molecular investigations. K E Y W O R D S B-cell lymphoma, B-cell lymphoproliferative disorders, flow cytometry, immunophenotype, Matutes score

show abstract

Lymphoplasmacytic lymphoma and Waldenström macroglobulinaemia: clinicopathological features and differential diagnosis

Cited by 25 publications

References 65 publications

Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenström Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma Cells

Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenström Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma Cells

CD5-Negative, CD10-Negative Low-Grade B-Cell Lymphoproliferative Disorders of the Spleen

Flow cytometry in the diagnosis of mature B‐cell lymphoproliferative disorders

Contact Info

Product

Resources

About